Researchers from New York-based Mount Sinai Health System have combined artificial intelligence, imaging and clinical data to rapidly detect COVID-19 in patients.
Precision medicine’s equivalent for people who are not necessarily ill, precision health, is only now starting to be developed.
The New York-based company claims its platform can be used to more accurately monitor efficacy of immunotherapy.
In this special report, seven experts in personalized medicine – from Accenture, CereCore, Chilmark Research, Deloitte and Orion Health – offer best practices for optimizing technology to help health systems advance innovation.
The organization, looking for ways to treat pathogens, will mine electronic health records of COVID-19 patients and use analytics to expedite research to find optimal treatment approaches.
"We see an enormous opportunity to enhance disease tracking for improved population health during the COVID-19 pandemic," said Scripps Research Translational Institute's Dr. Eric Topol.
Update: The HIMSS Global Conference in Orlando has been canceled due to the coronavirus. Read more here.
The pilot showcases an approach to AI integration that keeps impact on the radiologist's workflow to a minimum.
Update: HIMSS20 has been canceled due to the coronavirus. Read more here.
The five-year project will focus on enabling faster medical research innovations, protecting against global health crises and improving access to care, the company says.